Discontinued — last reported Q1 '26
Keytruda — Sales
Merck & Co. Keytruda — Sales decreased by 52.6% to $7.91B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 45.1%, from $14.41B to $7.91B. Over 4 years (FY 2021 to FY 2025), Keytruda — Sales shows an upward trend with a 16.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand and successful commercial execution, while a decrease may signal market saturation, competitive pressure, or loss of exclusivity.
Detailed definition
This metric represents the total gross revenue generated from the sale of a specific product line or therapeutic segment...
Peer comparison
Standard across all public companies as segment-level revenue reporting, allowing for direct comparison of product performance against industry peers.
mrk_segment_keytruda_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.35B | $9.07B | $9.15B | $9.62B | $10.50B | $10.85B | $10.90B | $11.59B | $12.54B | $12.68B | $13.21B | $13.89B | $14.54B | $14.86B | $15.67B | $14.41B | $15.91B | $16.28B | $16.68B | $7.91B |
| QoQ Change | — | +8.6% | +0.9% | +5.1% | +9.2% | +3.3% | +0.4% | +6.3% | +8.2% | +1.1% | +4.2% | +5.1% | +4.6% | +2.2% | +5.5% | -8.1% | +10.4% | +2.3% | +2.4% | -52.6% |
| YoY Change | — | — | — | — | +25.8% | +19.7% | +19.1% | +20.5% | +19.4% | +16.8% | +21.2% | +19.9% | +15.9% | +17.2% | +18.6% | +3.7% | +9.4% | +9.6% | +6.4% | -45.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s keytruda — sales?
- Merck & Co. (MRK) reported keytruda — sales of $7.91B in Q1 2026.
- How has Merck & Co.'s keytruda — sales changed year-over-year?
- Merck & Co.'s keytruda — sales decreased by 45.1% year-over-year, from $14.41B to $7.91B.
- What is the long-term trend for Merck & Co.'s keytruda — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s keytruda — sales has grown at a 16.5% compound annual growth rate (CAGR), from $34.37B to $63.28B.
- What does keytruda — sales mean?
- The total revenue earned from selling a specific product or service line.